Related Experiment Video

Updated: Jun 15, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Pharmacogenomics in the treatment of inflammatory bowel disease

Melissa A Smith1, Anthony M Marinaki, Jeremy D Sanderson

  • 1Department of Gastroenterology, 1st Floor, College House, St Thomas' Hospital, Lambeth Palace Road, London, SE1 7EH, UK.

Pharmacogenomics
|March 19, 2010
PubMed

Insights

Genetic variations impact inflammatory bowel disease treatment response and toxicity. Understanding pharmacogenomics can personalize therapies for better outcomes, moving beyond symptomatic relief to mucosal healing.

Area of Science:

  • Gastroenterology
  • Pharmacogenomics
  • Internal Medicine

Background:

  • Current inflammatory bowel disease (IBD) treatment aims for mucosal healing and altered disease course, not just symptom relief.
  • Despite advancements, many patients do not achieve treatment goals or experience adverse drug reactions.
  • Genetic factors are increasingly recognized as significant contributors to treatment variability in IBD.

Purpose of the Study:

  • To review the latest developments in pharmacogenomics for inflammatory bowel disease (IBD).
  • To highlight how genetic variations influence patient response and toxicity to IBD medications.
  • To provide guidance on translating pharmacogenomic findings into clinical practice for IBD management.

Main Methods:

  • Comprehensive literature review of pharmacogenomics in inflammatory bowel disease.
  • Analysis of genetic polymorphisms and their association with drug efficacy and safety.
  • Examination of established and emerging pharmacogenomic applications in IBD treatment.

Main Results:

  • Thiopurine methyltransferase (TPMT) polymorphism is a clinically established example influencing thiopurine therapy.
  • Emerging research identifies numerous other genetic variations affecting IBD drug response and toxicity.
  • Pharmacogenomic data offers potential for tailoring IBD treatments to individual patients.

Conclusions:

  • Pharmacogenomics holds significant promise for optimizing inflammatory bowel disease treatment strategies.
  • Personalized medicine approaches based on genetic profiles can improve therapeutic outcomes and reduce adverse events.
  • Further research and clinical integration of pharmacogenomics are crucial for advancing IBD care.

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...